Eli Lilly and Company $LLY is Journey Advisory Group LLC's 9th Largest Position

Key Points

• Journey Advisory Group LLC trimmed its position in Eli Lilly by 4.7% in Q4 to 22,055 shares, making LLY its 9th largest holding (~2.0% of assets) valued at about $23.7 million.
• Eli Lilly beat Q4 EPS estimates ($7.54 vs. $7.48) with revenue of $19.29 billion (+42.6% YoY) and set FY2026 EPS guidance of 33.50–35.00 (sell‑side consensus ~33.95).
• Analyst sentiment is broadly positive (consensus “Moderate Buy”, $1,225.33 target) as Lilly expands GLP‑1 distribution (Hims partnership) and reduces pipeline risk with completion of the LY3537982 renal study.

Journey Advisory Group LLC decreased its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 4.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 22,055 shares of the company's stock after selling 1,097 shares during the quarter. Eli Lilly and Company makes up about 2.0% of Journey Advisory Group LLC's holdings, making the stock its 9th biggest position. Journey Advisory Group LLC's holdings in Eli Lilly and Company were worth $23,702,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Maryland Capital Advisors Inc. bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at $25,000. Vermillion & White Wealth Management Group LLC raised its holdings in shares of Eli Lilly and Company by 84.2% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock valued at $27,000 after purchasing an additional 16 shares in the last quarter. 10Elms LLP raised its holdings in shares of Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company's stock valued at $31,000 after purchasing an additional 10 shares in the last quarter. Miller Global Investments LLC bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at $33,000. Finally, Hopwood Financial Services Inc. raised its holdings in shares of Eli Lilly and Company by 113.6% during the 3rd quarter. Hopwood Financial Services Inc. now owns 47 shares of the company's stock valued at $36,000 after purchasing an additional 25 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Expanded Hims & Hers partnership broadens distribution of Lilly's GLP‑1 weight‑loss drugs via Hims' platform—boosts patient access and recurring script volume potential. Eli Lilly (LLY) Expands Partnership with Hims & Hers
• Positive Sentiment: Hims will allow providers to prescribe scripts filled by LillyDirect, extending Lilly’s direct‑to‑consumer reach and potentially increasing channel efficiency for GLP‑1s. Hims Yields Ground in GLP-1 Market. Why Its CEO Is Calling It the Netflix of Pharma.
• Positive Sentiment: Phase 1 renal study of LY3537982 has completed, lowering early‑stage clinical risk for this asset and de‑risking part of Lilly’s pipeline. Eli Lilly’s LY3537982 Renal Study Reaches Completion, Reducing Early‑Stage Risk for LLY Investors
• Positive Sentiment: Analysts and strategists continue to back Lilly: Guggenheim raised its price target and maintained a buy stance, and Bernstein reiterated strong conviction ahead of Q1—supportive for sentiment and flows. Guggenheim Adjusts Price Target on Eli Lilly
• Positive Sentiment: Company is diversifying beyond GLP‑1s with the Kelonia acquisition and oncology focus (e.g., Verzenio and new launches), which underpins revenue diversification narratives. Eli Lilly Is More Than GLP-1 Drugs. The Stock Looks Attractive.
• Neutral Sentiment: Valuation pieces argue Lilly may still be attractively priced on long‑term metrics despite a high share price—useful for longer‑term investors but less relevant to near‑term moves. Is Eli Lilly Stock Actually ... Cheap? The Surprising Math Behind Its 2026 Valuation.
• Negative Sentiment: Analyst caution about the upcoming quarter: at least one wire notes Lilly lacks the ideal setup for an earnings beat next week, which raises short‑term risk to the stock if results or EPS guidance disappoint. Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
• Negative Sentiment: Recent intraday weakness and a recent session where LLY underperformed the market highlight short‑term volatility risk amid mixed headlines. Eli Lilly (LLY) Declines More Than Market: Some Information for Investors

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $917.94 on Friday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The firm's fifty day simple moving average is $961.94 and its 200 day simple moving average is $983.63. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54. The firm has a market capitalization of $867.29 billion, a PE ratio of 40.00, a PEG ratio of 1.09 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The business had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same period last year, the business posted $5.32 EPS. Eli Lilly and Company's revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 33.95 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the stock. Truist Financial restated a "buy" rating on shares of Eli Lilly and Company in a report on Monday, February 23rd. Scotiabank restated an "outperform" rating and set a $1,300.00 price target on shares of Eli Lilly and Company in a report on Thursday, February 5th. Argus raised their price target on shares of Eli Lilly and Company from $930.00 to $1,200.00 and gave the company a "buy" rating in a report on Monday, February 9th. UBS Group restated a "buy" rating on shares of Eli Lilly and Company in a report on Wednesday, March 18th. Finally, Zacks Research downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Friday, January 30th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $1,225.33.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.